PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock.

PDSB has been the subject of several other reports. B. Riley lowered their price objective on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, November 25th. StockNews.com cut shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.67.

PDS Biotechnology Stock Down 5.2 %

NASDAQ:PDSB opened at $1.27 on Monday. The firm has a market capitalization of $47.51 million, a price-to-earnings ratio of -1.09 and a beta of 1.88. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a twelve month low of $1.20 and a twelve month high of $6.68. The stock’s 50 day moving average price is $1.56 and its two-hundred day moving average price is $2.46.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Marshall Wace LLP increased its holdings in PDS Biotechnology by 38.4% in the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock worth $64,000 after buying an additional 10,837 shares in the last quarter. Raymond James Financial Inc. purchased a new position in PDS Biotechnology during the fourth quarter valued at approximately $26,000. Jane Street Group LLC purchased a new stake in shares of PDS Biotechnology in the fourth quarter worth $58,000. Blair William & Co. IL grew its position in shares of PDS Biotechnology by 29.4% during the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock worth $257,000 after purchasing an additional 35,757 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of PDS Biotechnology by 9.8% in the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after buying an additional 37,142 shares in the last quarter. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.